MCPP

1. 2026-10-19issueIssued info_card
2. 2026-09-07srcEvidence for noncompetitive modulation of substrate-induced serotonin release
3. 2026-09-07srcDetermining the subjective effects of TFMPP in human males
4. 2026-09-07srcLinking the pharmacological content of ecstasy tablets to the subjective experiences of drug users
5. 2026-09-07srcEffects of the 5-HT2C receptor agonist meta-chlorophenylpiperazine on appetite, food intake and emotional processing in healthy volunteers
6. 2026-09-07srcThe 5-HT2C receptor agonist meta-chlorophenylpiperazine (mCPP) reduces palatable food consumption and BOLD fMRI responses to food images in healthy female volunteers
7. 2026-09-07srcNeurotoxicity screening of (illicit) drugs using novel methods for analysis of microelectrode array (MEA) recordings
8. 2026-09-07srcMeta-Chlorophenylpiperazine-Induced Behavioral Changes in Obsessive-Compulsive Disorder Research: A Systematic Review of Rodent Studies
9. 2026-09-07srcEvidence for a role of transporter-mediated currents in the depletion of brain serotonin induced by serotonin transporter substrates
10. 2026-09-07srcMetabolism of m-CPP, trazodone, nefazodone, and etoperidone: clinical and forensic aspects
11. 2026-09-07srcTrazodone generates m-CPP: in 2008 risks from m-CPP might outweigh benefits of trazodone
12. 2026-09-07srcAcute chlorophenylpiperazine overdose: a case report and review of the literature
13. 2026-09-07srcA fatality following ingestion of the designer drug meta-chlorophenylpiperazine (mCPP) in an asthmatic--HPLC-MS/MS detection in biofluids and hair
14. 2026-09-07srcDetection of novel reactive metabolites of trazodone: evidence for CYP2D6-mediated bioactivation of m-chlorophenylpiperazine
15. 2026-09-07srcCharacterization of trazodone metabolic pathways and species-specific profiles
16. 2026-09-07srcNefazodone, meta-chlorophenylpiperazine, and their metabolites in vitro: cytochromes mediating transformation, and P450-3A4 inhibitory actions
17. 2026-09-07srcAltered neuroendocrine and behavioral responses to m-chlorophenylpiperazine in 3,4-methylenedioxymethamphetamine (MDMA) users
18. 2026-09-07srcAltered prolactin response to M-chlorophenylpiperazine in monkeys previously treated with MDMA or fenfluramine
19. 2026-09-07srcm-CPP hypolocomotion is selectively antagonized by compounds with high affinity for 5-HT2C receptors but not 5-HT2A or 5-HT2B receptors
20. 2026-09-07srcp-Methylthioamphetamine and 1-(m-chlorophenyl)piperazine, two non-neurotoxic 5-HT releasers in vivo, differ from neurotoxic amphetamine derivatives in their mode of action at 5-HT nerve endings in vitro
21. 2026-09-07srcThe effects of gender and gonadal steroids on the neuroendocrine and temperature response to m-chlorophenylpiperazine in leuprolide-induced hypogonadism in women and men
22. 2026-09-07srcCentral serotonergic effects of m-chlorophenylpiperazine (mCPP) among normal control adolescents
23. 2026-09-07srcPharmacokinetics of m-chlorophenylpiperazine after intravenous and oral administration in healthy male volunteers: implication for the pharmacodynamic profile
24. 2026-09-07srcN-substituted piperazines abused by humans mimic the molecular mechanism of 3,4-methylenedioxymethamphetamine (MDMA, or 'Ecstasy')
25. 2026-09-07srcRelationship of disinhibition and aggression to blunted prolactin response to meta-chlorophenylpiperazine in cocaine-dependent patients
26. 2026-09-07srcm-Chlorophenylpiperazine as a probe of serotonin function
27. 2026-09-07srcMetachlorophenylpiperazine (mCPP): a new designer drug
28. 2026-09-07srcEffects of ritanserin on the behavioral, neuroendocrine, and cardiovascular responses to meta-chlorophenylpiperazine in healthy human subjects
29. 2026-09-07srcProof of a 1-(3-chlorophenyl)piperazine (mCPP) intake: use as adulterant of cocaine resulting in drug-drug interactions?
30. 2026-09-07srcPossible pharmacological probes for predicting and preventing relapse in treated alcoholics
31. 2026-09-07srcMetergoline blocks the behavioral and neuroendocrine effects of orally administered m-chlorophenylpiperazine in patients with obsessive-compulsive disorder
32. 2026-09-07srcTrazodone, meta-chlorophenylpiperazine (an hallucinogenic drug and trazodone metabolite), and the hallucinogen trifluoromethylphenylpiperazine cross-react with the EMIT II ecstasy immunoassay in urine
33. 2026-09-07srcObsessive-compulsive disorder: psychobiological approaches to diagnosis, treatment, and pathophysiology
34. 2026-09-07srcInduction of depersonalization by the serotonin agonist meta-chlorophenylpiperazine
35. 2026-09-07srcSerotonin and thermoregulation. Physiologic and pharmacologic aspects of control revealed by intravenous m-CPP in normal human subjects
36. 2026-09-07srcDiscriminative stimulus properties of mCPP: evidence for a 5-HT2C receptor mode of action
37. 2026-09-07src1-(3-Chlorophenyl)piperazine | PubChem CID 1355
38. 2026-09-07srcNCT03962829 - Effect of mCPP on Cognitive Control, Appetite, and Neural Responses
39. 2026-09-07src5-HT2C Receptor Entry: mCPP binding data
40. 2026-09-07srcNCT00605904 - Modulation of Pharmacologically Induced Alcohol Craving in Recently Detoxified Alcoholics
41. 2026-09-07srcmCPP legal status - Wikipedia
42. 2026-09-04issueIssued emergency
43. 2026-09-04issueIssued info_card
44. 2026-09-04issueIssued notice
45. 2026-06-04proposal31 value proposals approved togetherone review action inferred from a shared reviewer and instant — the graph records one activity per proposal
46. 2026-06-04publicationPublication — backfill
47. 2026-05-12revisionRevision 1
48. 2026-05-11genGeneration — pipeline-v5 · with 13 morepipeline-v5
49. 2026-05-11rungeneration run

The same entries, as forms: six forms.